CTOs on the Move

NeuroBo Pharmaceuticals

www.neurobopharma.com

 
NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NeuroBo Pharmaceuticals raised $10M on 01/19/2021

Similar Companies

AA Medical

AA Medical Store improves healthcare around the world by supplying refurbished state-of the-art surgical devices at the best price, with the best warranty, and unmatched service and support.

Janssen Pharmaceuticals

Janssen Pharmaceuticals is a Titusville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Organigram

Founded in 2013, Organigram is a leading Canadian licensed producer, focused on producing high-quality, indoor-grown cannabis for adult recreational consumers in all provinces and the Yukon. Headquartered in Toronto, Organigram has three state-of-the-art cultivation and processing facilities in Moncton, Winnipeg and Lac-Supérieur, and its adult-use products can be found in retail outlets from coast-to-coast. Organigram`s adult-use brands include Edison, SHRED, monjour, Laurentian Cannabis, Holy Mountain, Big Bag O`Buds, Tremblant Cannabis and Trailblazer.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.

Vishay BLH

BLH provides precision load cells, weight and force measurement systems, strain gages, web tension transducers, and instrumentation